Gmd-Binding Antibodies for Resistant Staphylococcus Growth Inhibition

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

The growing prevalence of antimicrobial-resistant Staphylococcus aureus strains has limited therapeutic options and increased healthcare costs, necessitating alternative methods for prevention and treatment of infections.

Innovation Solution

Development of glucosaminidase (Gmd)-binding antibodies that inhibit the growth of Staphylococcus aureus, including resistant strains, through various mechanisms such as inhibiting growth, promoting clumping, and cell lysis, with specific antibody fragments designed to target and bind to Gmd with high affinity.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If conventional antimicrobial agents are used to treat Staphylococcus infections, then infection treatment is effective, but antimicrobial resistance develops and therapeutic options are limited

Engineering Contradiction:

Improveeffectiveness of infection treatmentVSAvoidtherapeutic options

Core Design Contradiction:

ReliabilityVSAdaptability or versatility

Solution Approach 1:

The patent uses glucosaminidase (Gmd) as an intermediary target - a bacterial enzyme essential for cell wall synthesis - and develops antibodies that bind to Gmd, thereby indirectly inhibiting bacterial growth. This intermediary approach allows treatment of resistant strains without directly targeting the bacteria with conventional antimicrobials, expanding therapeutic options while maintaining effectiveness.

Inventive Principle:

Principle #24Intermediary (Mediator)

Solution Approach 2:

The patent replaces conventional chemical antimicrobial agents with a biological mechanism - antibody-mediated inhibition of Gmd. Instead of using chemicals that directly kill or inhibit bacteria, the system uses proteins (antibodies) that bind to a specific bacterial enzyme, substituting the mechanical/chemical action with a biochemical interaction that overcomes antimicrobial resistance.

Inventive Principle:

Principle #28Mechanics substitution (Replace mechanical system)

2Reliability

If Gmd-binding antibodies are developed to target resistant strains, then therapeutic effectiveness is improved, but development complexity and cost increase

Engineering Contradiction:

Improvetherapeutic effectivenessVSAvoidantibody development complexity

Core Design Contradiction:

ReliabilityVSDevice complexity

Solution Approach 1:

The patent identifies Gmd as a universal target across different Staphylococcus strains, including resistant strains. By developing antibodies against this conserved enzyme, a single therapeutic approach can effectively treat multiple strains and infection types (skin, soft tissue, invasive infections), providing multi-functionality that justifies the development investment.

Inventive Principle:

Principle #6Universality (Multi-functionality)

Solution Approach 2:

The patent optimizes antibody parameters including binding affinity (KD ≤1 nM and ≥1 pM), epitope specificity, and functional characteristics (growth inhibition, clumping promotion, lysis induction). By carefully controlling these parameters, the patent achieves high therapeutic effectiveness while managing development complexity through systematic optimization rather than trial-and-error.

Inventive Principle:

Principle #35Parameter changes

3Reliability

If multiple antibody characteristics are required (growth inhibition, clumping promotion, lysis induction), then therapeutic performance is enhanced, but manufacturing and characterization difficulty increase

Engineering Contradiction:

Improvetherapeutic performanceVSAvoidantibody manufacturing and characterization

Core Design Contradiction:

ReliabilityVSEase of manufacture

Solution Approach 1:

The patent segments the therapeutic effects into distinct functional characteristics: growth inhibition, clumping promotion, and lysis induction. By evaluating and optimizing each characteristic separately through defined assays, the patent manages the complexity of achieving multiple effects. The segmentation allows systematic development and characterization, making the manufacturing process more manageable despite the multiple required functions.

Inventive Principle:

Principle #1Segmentation

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

The Gmd-binding antibodies effectively inhibit Staphylococcus aureus growth by 20% to 100%, offering therapeutic options for infections and conditions associated with Staphylococcus, including resistant strains like MRSA, and facilitate diagnostic and prognostic methods.

Implementation Method 1

Gmd-binding antibodies (e.g., full length antibodies and Gmd-binding antibody fragments) capable of inhibiting growth of Staphylococcus

Methodology Applied

Scientific EffectAntibody binding:

Implementation Method 2

promotes clumping (clustering) of S. aureus

Methodology Applied

Scientific EffectClumping: Coagulation

Implementation Method 3

promotes cell-independent lysis of S. aureus

Methodology Applied

Scientific EffectCell lysis:

Data Source

PatentUS20250277058A1Antibodies that bind glucosaminidase and uses thereof

Publication Date: 2025.09.04 TELEPHUS BIOSCIENCES LLC

AI summary

This disclosure provides glucosaminidase (Gmd)-binding antibodies capable of inhibiting growth of Staphylococcus and methods of making and using these antibodies in for example, diagnostic prognostic methods, and therapeutic applications. The disclosure further provides methods for treating a Staphylococcus (e.g., S. aureus) infection using the Gmd-binding antibodies. Methods for treating conditions associated with microbial infections including for example, fever, bacteremia, endocarditis, osteomyelitis, pneumonia, sepsis, septic shock, dermonecrosis, and mastitis are also provided.